Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medication

U.N. Report: Over Half of People with HIV Having Treatment for First Time

London, September 15, 2017 — The Associated Press’ Maria Cheng reported in July that, for the first time in the global AIDS epidemic that has spanned four decades and killed 35 million people, more than half of all those infected with HIV are on drugs to treat the virus, the United Nations said in a report released Thursday.

AIDS deaths are also now close to half of what they were in 2005, according to the U.N. AIDS agency, although those figures are based on estimates and not actual counts from countries.

Experts applauded the progress, but questioned if the billions spent in the past two decades should have brought more impressive results. The U.N. report was released in Paris where an AIDS meeting begins this weekend. Continue reading

Express Scripts: The Cost of Not Taking Medications as Prescribed Is $330 Billion

Washington, DC, September 24, 2015 ― Elizabeth O’Brien reports in MarketWatch that pharmacy benefit manager Express Scripts’ 2014 Drug Trend Report found that prescription non-adherence costs the US roughly $330 billion a year in unnecessary medical complications.  The report breaks down adherence by ailment, and the numbers are startling.

While people sometimes scrimp on medications to save money, this can lead to bigger health problems with bigger price tags, like a trip to the emergency room.

The Express Scripts 2014 Drug Trend Report breaks down adherence by ailment, and the numbers are startling. Continue reading